Clinical Performance Evaluation of SARS-CoV-2 (COVID-19) Antigen Assay in Point of Care Settings

Completed

• Conditions: Covid-19
• Interventions: Device: SARS-CoV-2 Antigen Assay

• Registration Number: NCT05213897
• Lead Sponsor: Freedom For All Diagnostics

Brief Summary

The purpose of this study is to evaluate the performance of Freedom For All Diagnostics, Inc.'s colloidal gold immune technology SARS-CoV-2 Antigen investigational assay when compared to a high-sensitivity Emergency Use Authorization (EUA) SARS-CoV-2 RT-PCR assay. The study will evaluate the accuracy in the intended use environment of the SARS-CoV-2 antigen assay when testing is conducted in a CLIA-waived setting (e.g., a physician's office or clinic) by non-laboratory personnel serving in a healthcare facility or setting.

Detailed Description

The objective of this study is to demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples. This study is designed as a prospective, blinded study to evaluate the sensitivity and specificity of the SARS-CoV-2 Antigen Assay when non-laboratory personnel conduct testing on Subjects presenting with symptoms of COVID-19.

A minimum of 30 positive and 30 negative samples are required in order to meet EUA submission guidelines. Enrollment will continue until both minimum requirements have been achieved.

Study Timeline

• Study First Submitted: 2022-01-25
• Study First Submitted QC: 2022-01-25
• Study Start: 2022-01-27
• Study First Posted: 2022-01-28
• Status Verified: 2022-06
• Primary Completion: 2022-06-01
• Study Completion: 2022-06-01
• Last Update Submitted: 2022-06-01
• Last Update Posted: 2022-06-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 232

Inclusion Criteria

• Subject suspected of having COVID-19 infection and within 7 days of symptom onset. This will include at least one of the following:

  • Fever or chills
  • Cough
  • Shortness of breath or difficulty breathing
  • Fatigue
  • Muscle or body aches
  • Headache
  • New loss of taste or smell
  • Sore throat
  • Congestion or runny nose

• In addition to the above primary symptoms, the Subject might also report nausea, vomiting and/or diarrhea, but these symptoms alone are not sufficient to include the Subject in the study.

• Subject is willing to provide consent/assent.

• Subject is willing to have two (2) nasopharyngeal swabs collected for the study and in the event of inconclusive results, be willing to return to the site to have two (2) more nasopharyngeal swabs

Exclusion Criteria

To be enrolled in the study, each Subject must not meet:

• Subject unable or unwilling to provide informed consent/assent.
• Subject tested positive for SARS-CoV-2 within the past 3 months.
• Subject has already participated in this study.
• Subject is a vulnerable population and deemed inappropriate for study by site Principal Investigator and/or IRB.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
30 subjects testing negative for Covid-19	SARS-CoV-2 Antigen Assay	30 subjects testing negative for Covid-19 using the proprietary SARS-CoV-2 Antigen Assay
30 subjects testing positive for Covid-19	SARS-CoV-2 Antigen Assay	30 subjects testing positive for Covid-19 using the proprietary SARS-CoV-2 Antigen Assay

Primary Outcome Measures

Name	Time	Method
Assay Sensitivity - 80% (versus the EUA SARS-CoV-2 RT-PCR assay)	48 hours	SARS-CoV-2 Antigen investigational assay shall have an observed sensitivity of at least 80% when the EUA SARS-CoV-2 RT-PCR assay for nasopharyngeal swabs is used as a reference method.

Trial Locations

Locations (1)

Centennial Medical; 🇺🇸 Elkridge, Maryland, United States